AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9736819 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype analysis
Number of subjects: 6
Study 9736819 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load assessment
Number of subjects: 6
Study 8036962 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss program
Number of subjects: 186
Study 2929526 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral obesity treatment
Number of subjects: 56
Study 2929526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 56
Study 2929526 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 5 years (small sample of treated children)
Number of subjects: 56
Study 30903287 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 200 μg
Number of subjects: 180
Study 30903287 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oestradiol 100 μg
Number of subjects: 180
Study 30903287 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 180
Study 30073445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for drug administration
Number of subjects: 74
Study 30073445 — intervention group
Group type: COMPARATOR
Intervention: Control scenarios (without app)
Number of subjects: 74
Study 28363526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam (2000/500 mg, 2-h infusion) plus metronidazole (500 mg, 60-min infusion)
Number of subjects: 441
Study 28363526 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1000 mg, 30-min infusion)
Number of subjects: 441
Study 28363526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam plus metronidazole
Number of subjects: 441
Study 28363526 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/avibactam plus metronidazole and Meropenem
Number of subjects: 441
Study 25315664 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with outer retinal tubulation (ORT)
Number of subjects: 108
Study 25315664 — intervention group
Group type: COMPARATOR
Intervention: Eyes without outer retinal tubulation (ORT)
Number of subjects: 108
Study 25315664 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with ORT (multifocal GA lesions)
Number of subjects: 108
Study 25315664 — intervention group
Group type: COMPARATOR
Intervention: Eyes without ORT (multifocal GA lesions)
Number of subjects: 108
Study 25315664 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with ORT (unifocal GA lesions)
Number of subjects: 108
Study 25315664 — intervention group
Group type: COMPARATOR
Intervention: Eyes without ORT (unifocal GA lesions)
Number of subjects: 108
Study 23269782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual education intervention
Number of subjects: 52
Study 23269782 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 52
Study 21718775 — intervention group
Group type: EXPERIMENTAL
Intervention: Portulaca oleracea (PO) seeds, 5 g twice daily
Number of subjects: 30
Study 21718775 — intervention group
Group type: COMPARATOR
Intervention: Metformin, 1,500 mg/day
Number of subjects: 30
Study 18640386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ERT
Number of subjects: 41
Study 18640386 — intervention group
Group type: COMPARATOR
Intervention: Transdermal ERT
Number of subjects: 41
Study 16595206 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC (104 mg)
Number of subjects: 274
Study 16595206 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (11.25 mg)
Number of subjects: 274
Study 12874697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenous infusion)
Number of subjects: 46
Study 12874697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11874941 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-Tocopherol supplementation (1,200 IU/day)
Number of subjects: 72
Study 11874941 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 72
Study 9428817 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1.0 mg/kg body weight, administered intravenously before transplantation and once every other week afterward for a total of five doses)
Number of subjects: 260
Study 9428817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intravenously before transplantation and once every other week afterward for a total of five doses)
Number of subjects: 260
Study 9428817 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 260
Study 9428817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 8608061 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic CSF
Number of subjects: 0
Study 8608061 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CSF
Number of subjects: 0
Study 8608061 — intervention group
Group type: COMPARATOR
Intervention: No CSF
Number of subjects: 0
Study 2501243 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus mitomycin C
Number of subjects: 120
Study 2501243 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 120
Study 831472 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Number of subjects: 120
Study 831472 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of heparin 1,000 units to each liter of intravenous fluid
Number of subjects: 120
Study 831472 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of heparin 500 units and hydrocortisone phosphate 1 mg to each liter of intravenous fluid
Number of subjects: 120
Study 831472 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of heparin 1,000 units and hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Number of subjects: 120
Study 831472 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of intravenous solutions through a 0.22‐mum inline filter
Number of subjects: 120
Study 831472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 120
Study 31938571 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Interferential Current stimulation (IFC) with medium frequency of 4000 HZ
Number of subjects: 46
Study 31938571 — intervention group
Group type: COMPARATOR
Intervention: Electrical Acupuncture (EAC) two times a week for a total of 10 sessions
Number of subjects: 46
Study 31694152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed flavonoid-caffeine (MFC) supplement (658 mg flavonoids, 214 mg caffeine)
Number of subjects: 19
Study 31694152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed flavonoid-caffeine (MFC) supplement
Number of subjects: 19
Study 31694152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 28364726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 48
Study 28364726 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 48
Study 25936297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg l‐methionine to induce hyperhomocysteinemia
Number of subjects: 25
Study 25936297 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml whipping cream (30% fat) to induce hyperlipidemia
Number of subjects: 25
Study 25936297 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline assessment)
Number of subjects: 25
Study 23054169 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) coalitions
Number of subjects: 0
Study 23054169 — intervention group
Group type: COMPARATOR
Intervention: Control coalitions
Number of subjects: 0
Study 23054169 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Economic Problems scale
Number of subjects: 0
Study 23054169 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC coalitions
Number of subjects: 0
Study 21270630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen (2:1 mixture)
Number of subjects: 20
Study 21270630 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane in air-oxygen)
Number of subjects: 20
Study 18800037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil administered for up to 7 days
Number of subjects: 36
Study 16490627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril, 2.5 mg 3 times/wk
Number of subjects: 46
Study 16490627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16490627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 46
Study 15256981 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment followed by Helicobacter pylori test and treat strategy (treat and test group)
Number of subjects: 77
Study 15256981 — intervention group
Group type: COMPARATOR
Intervention: Prompt upper gastrointestinal endoscopy (endoscopy group)
Number of subjects: 77
Study 11078839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the right eye
Number of subjects: 60
Study 11078839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the superior neuroretinal rim of the right eye
Number of subjects: 60
Study 11078839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the superior neuroretinal rim of the left eye
Number of subjects: 60
Study 11078839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the left eye
Number of subjects: 60
Study 11078839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the inferior temporal neuroretinal rim of the right eye
Number of subjects: 60
Study 11078839 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the inferior temporal neuroretinal rim of the left eye
Number of subjects: 60
Study 9305482 — intervention group
Group type: EXPERIMENTAL
Intervention: AIMg(OH)3 (280 mval/day)
Number of subjects: 174
Study 9305482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 174
Study 9305482 — intervention group
Group type: COMPARATOR
Intervention: AIMg(OH)3 and Ranitidine
Number of subjects: 174
Study 8342399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (4 micrograms/kg loading dose followed by 1 microgram/kg/h infusion)
Number of subjects: 20
Study 8342399 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study 30893689 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive wrap applied immediately after birth
Number of subjects: 28
Study 30893689 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no wrap)
Number of subjects: 28
Study 29549193 — intervention group
Group type: EXPERIMENTAL
Intervention: ELEVIDA (self-guided online fatigue management programme)
Number of subjects: 275
Study 29549193 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 275
Study 27639819 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 0.5 mg/kg, twice daily (max 60 mg/day) from day one until discharge
Number of subjects: 100
Study 27639819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 100
Study 27639819 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer assay
Number of subjects: 100
Study 27639819 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS)
Number of subjects: 100
Study 27639819 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer values
Number of subjects: 100
Study 24708506 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from the United States sorting images of posed facial expressions with cues to emotion concepts.
Number of subjects: 0
Study 24708506 — intervention group
Group type: COMPARATOR
Intervention: Participants from the Himba ethnic group sorting images of posed facial expressions without cues to emotion concepts.
Number of subjects: 0
Study 24708506 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from both cultures sorting images of posed facial expressions with cues to emotion concepts.
Number of subjects: 0
Study 22504187 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) simulator
Number of subjects: 24
Study 22504187 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 24
Study 22504187 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 24
Study 20214176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hemostatic powder (THP)
Number of subjects: 24
Study 20214176 — intervention group
Group type: COMPARATOR
Intervention: Sterile compressed surgical sponge
Number of subjects: 24
Study 18653654 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 102
Study 18653654 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 102
Study 15640999 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive cervical spine surgery
Number of subjects: 26
Study 12496983 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic injection of 5 ml 1% lidocaine solution (2.5 ml bilaterally)
Number of subjects: 100
Study 12496983 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (Control)
Number of subjects: 100
Study 10502030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure pea starch
Number of subjects: 26
Study 10502030 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch
Number of subjects: 26
Study 10502030 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude pea flour
Number of subjects: 26
Study 9156938 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative drug addicts (1986-87)
Number of subjects: 91
Study 9156938 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive drug addicts
Number of subjects: 91
Study 9156938 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS patients
Number of subjects: 91
Study 9156938 — intervention group
Group type: EXPERIMENTAL
Intervention: All investigated groups
Number of subjects: 91
Study 9156938 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 91
Study 1859008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1 bolus followed by infusion of 160 microgram.kg‐1.min‐1
Number of subjects: 120
Study 1859008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (as in group B) and 66% N2O
Number of subjects: 120
Study 1859008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (as in group B), 66% N2O (as in group C), and droperidol 75 micrograms.kg‐1
Number of subjects: 120
Study 1859008 — intervention group
Group type: COMPARATOR
Intervention: Halothane, 66% N2O, and droperidol 75 micrograms.kg‐1
Number of subjects: 120
Study 6344981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and high-dose methotrexate
Number of subjects: 65
Study 6344981 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 65
Study 31341170 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN-resistant soybean cultivars infested with 2000 nematode eggs and 15 soybean aphids at V2 growth stage
Number of subjects: 6
Study 31341170 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN-susceptible soybean cultivars infested with 2000 nematode eggs and 15 soybean aphids at V2 growth stage
Number of subjects: 6
Study 28617733 — intervention group
Group type: COMPARATOR
Intervention: Facility-based HIV testing and counseling (HTC)
Number of subjects: 325
Study 28617733 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 325
Study 28925135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii glycosides (20 mg, tid for 4 weeks, then 10 mg, tid) combined with gestrinone (2.5 mg on 1st and 4th day of menstrual cycle, then twice a week)
Number of subjects: 135
Study 28925135 — intervention group
Group type: COMPARATOR
Intervention: Gestrinone capsule (same intake method as treatment group)
Number of subjects: 135
Study 28925135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii glycosides combined with gestrinone
Number of subjects: 135
Study 24366350 — intervention group
Group type: EXPERIMENTAL
Intervention: Free bednet distribution program
Number of subjects: 560
Study 20664362 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Stimuli (VS)
Number of subjects: 15
Study 20664362 — intervention group
Group type: COMPARATOR
Intervention: Auditory Stimuli (AS)
Number of subjects: 15
Study 19418075 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial educational program (PSEP) consisting of an interactive seminar and the Back Book for reference material.
Number of subjects: 3792
Study 19418075 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no education.
Number of subjects: 3792
Study 19418075 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial educational program (PSEP)
Number of subjects: 3792
Study 17578820 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 160
Study 17578820 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic surgeons
Number of subjects: 160
Study 15219610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 8
Study 15219610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11356439 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational reminder messages
Number of subjects: 244
Study 11356439 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 244
Study 9492127 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection within the wound (0.5 mL buffered lidocaine)
Number of subjects: 63
Study 9492127 — intervention group
Group type: COMPARATOR
Intervention: Injection through intact skin (0.5 mL buffered lidocaine)
Number of subjects: 63
Study 9492127 — intervention group
Group type: EXPERIMENTAL
Intervention: First injection (within wound) in group 1
Number of subjects: 63
Study 9492127 — intervention group
Group type: COMPARATOR
Intervention: Second injection (intact skin) in group 1
Number of subjects: 63
Study 9492127 — intervention group
Group type: EXPERIMENTAL
Intervention: First injection (intact skin) in group 2
Number of subjects: 63
Study 9492127 — intervention group
Group type: COMPARATOR
Intervention: Second injection (within wound) in group 2
Number of subjects: 63
Study 8113006 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol (0.25%)
Number of subjects: 20
Study 8113006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3381775 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength formula (equal parts, 84 J/30 mL [20 cal/oz] formula and water)
Number of subjects: 50
Study 3381775 — intervention group
Group type: COMPARATOR
Intervention: Full-strength (FS) formula (84 J/30 mL [20 cal/oz])
Number of subjects: 50
Study 30547963 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship-focused healthcare visit
Number of subjects: 44
Study 30547963 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 44
Study 28151914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 119
Study 28151914 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 26559307 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified trephine
Number of subjects: 50
Study 26559307 — intervention group
Group type: COMPARATOR
Intervention: High-speed drill
Number of subjects: 50
Study 23596140 — intervention group
Group type: COMPARATOR
Intervention: Physician intervention
Number of subjects: 1000
Study 23596140 — intervention group
Group type: COMPARATOR
Intervention: Physician plus patient intervention
Number of subjects: 1000
Study 21775504 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterpretable Risk Score (URS) developed using clinical and patient variables (heart rate and coronary calcium).
Number of subjects: 9500
Study 21775504 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased heart rate and coronary artery calcium score.
Number of subjects: 9500
Study 21775504 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterpretable results from CCTA.
Number of subjects: 9500
Study 19840653 — intervention group
Group type: EXPERIMENTAL
Intervention: GT rotary files
Number of subjects: 20
Study 19840653 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper rotary files
Number of subjects: 20
Study 19840653 — intervention group
Group type: COMPARATOR
Intervention: ProTaper and GT rotary files
Number of subjects: 20
Study 16624446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheeseburger stimulus
Number of subjects: 0
Study 16624446 — intervention group
Group type: COMPARATOR
Intervention: French fries (novel stimulus)
Number of subjects: 0
Study 16624446 — intervention group
Group type: COMPARATOR
Intervention: Cheeseburger (repeated stimulus)
Number of subjects: 0
Study 16624446 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated responding
Number of subjects: 0
Study 15523983 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon CustomCornea LASIK
Number of subjects: 35
Study 15523983 — intervention group
Group type: COMPARATOR
Intervention: VISX CustomVue LASIK
Number of subjects: 35
Study 15523983 — intervention group
Group type: COMPARATOR
Intervention: CustomVue LASIK
Number of subjects: 35
Study 15523983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 35
Study 11878727 — intervention group
Group type: EXPERIMENTAL
Intervention: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural bupivacaine (Bupi)
Number of subjects: 60
Study 11878727 — intervention group
Group type: EXPERIMENTAL
Intervention: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural saline (Saline)
Number of subjects: 60
Study 11878727 — intervention group
Group type: COMPARATOR
Intervention: GA, paracetamol, NSAID (GA)
Number of subjects: 60
Study 9741867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (60% of participants)
Number of subjects: 750
Study 9741867 — intervention group
Group type: COMPARATOR
Intervention: Control (40% of participants)
Number of subjects: 750